| 41.03 0 (0%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 48.05 | 1-year : | 56.12 |
| Resists | First : | 41.13 | Second : | 48.05 |
| Pivot price | 41  |
|||
| Supports | First : | 40.86 |
Second : | 40.7 |
| MAs | MA(5) : | 41.03 | MA(20) : | 40.98 |
| MA(100) : | 27.98 |
MA(250) : | 24.57 |
|
| MACD | MACD : | 1.6 |
Signal : | 2.2 |
| %K %D | K(14,3) : | 55.1 |
D(3) : | 59.3 |
| RSI | RSI(14): 84.4 | |||
| 52-week | High : | 41.13 | Low : | 16.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ APLS ] has closed below upper band by 36.5%. Bollinger Bands are 97.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 18 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 41.07 - 41.27 | 41.27 - 41.44 |
| Low: | 40.54 - 40.78 | 40.78 - 40.98 |
| Close: | 40.68 - 41.04 | 41.04 - 41.35 |
Apellis Pharmaceuticals, Inc. is an actively operating biopharmaceutical enterprise dedicated to the discovery, advancement, and commercialization of therapeutic agents. Its core strategy involves modulating the complement system to address various autoimmune and inflammatory conditions. The company's primary investigational compound, pegcetacoplan, is currently undergoing Phase III clinical evaluation. This advanced-stage therapy is being explored for its potential in treating geographic atrophy (GA), a form of age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH). Beyond this lead candidate, Apellis also offers EMPAVELI (a systemic formulation of pegcetacoplan), which is being developed for a range of indications: in hematology for cold agglutinin disease (CAD) and thrombotic microangiopathy associated with hematopoietic stem cell transplantation (HSCT-TMA); in nephrology for C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN); and in neurology for amyotrophic lateral sclerosis (ALS). Furthermore, Apellis boasts a diverse pipeline including APL-2006, a dual-action C3 and VEGF inhibitor designed for complement-mediated disorders; APL-1030, a C3 inhibitor targeting multiple neurodegenerative diseases; and a novel combination therapy involving EMPAVELI with small interfering RNA (siRNA) to reduce hepatic C3 protein synthesis. Strategic alliances play a significant role, with a collaboration and licensing agreement in place with Swedish Orphan Biovitrum AB (publ) for the joint development of pegcetacoplan. The company also maintains a research partnership with Beam Therapeutics Inc., focusing on leveraging Beam's base editing technology to uncover new treatments for illnesses driven by complement system dysregulation. Established in 2009, Apellis Pharmaceuticals, Inc. operates from its headquarters in Waltham, Massachusetts.
Fri, 05 Jun 2026
Apellis (APLS) Amendment: Morgan Stanley Reports - Stock Titan
Tue, 26 May 2026
[15-12G] Apellis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Tue, 19 May 2026
Apellis Pharmaceuticals (NASDAQ:APLS) Shines in Navellier’s Growth Screen With Strong Earnings and Revenue Momentum - ChartMill
Thu, 14 May 2026
Biogen Completes Acquisition of Apellis Pharmaceuticals - Biogen
Thu, 07 May 2026
Apellis Pharmaceuticals, Inc. (APLS) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Mon, 27 Apr 2026
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS): A Fitting GARP Opportunity - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 128 (M) |
| Shares Float | 83 (M) |
| Held by Insiders | 11.3 (%) |
| Held by Institutions | 110.4 (%) |
| Shares Short | 10,750 (K) |
| Shares Short P.Month | 25,120 (K) |
| EPS | 1.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.24 |
| Profit Margin | 12 % |
| Operating Margin | 9.8 % |
| Return on Assets (ttm) | 10.9 % |
| Return on Equity (ttm) | 46 % |
| Qtrly Rev. Growth | 60.9 % |
| Gross Profit (p.s.) | 5.54 |
| Sales Per Share | 8.67 |
| EBITDA (p.s.) | 1.3 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 38 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | 38.34 |
| PEG Ratio | 0 |
| Price to Book value | 12.66 |
| Price to Sales | 4.73 |
| Price to Cash Flow | 139.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|